KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab plus Chemotherapy for Metastatic Nonsquamous NSCLC

被引：4
|
作者：
Gadgeel, S. [1 ]
Garassino, M. C. [2 ]
Esteban, E. [3 ]
Speranza, G. [4 ]
Felip, E. [5 ]
Hochmair, M. J. [6 ,7 ]
Powell, S. [8 ]
Cheng, S. Y. -S. [9 ]
Bischoff, H. G. [10 ]
Peled, N. [11 ]
Hui, R. [12 ,13 ]
Reck, M. [14 ]
Kurata, T. [15 ]
Garon, E. B. [16 ]
Boyer, M. [17 ]
Yang, J. [18 ]
Pietanza, M. C. [18 ]
Rodriguez-Abreu, D. [19 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[3] Hosp Univ Cent Asturias, Oviedo, Spain
[4] Univ Sherbrooke, Ctr Integre Cancerol Monteregie, Greenfield Pk, PQ, Canada
[5] Vall dHebron Univ, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[6] Dept Resp & Crit Care Med, Vienna, Austria
[7] Ludwig Boltzmann Inst COPD & Resp Epidemiol, Vienna, Austria
[8] Sanford Hlth, Sioux Falls, SD USA
[9] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[10] Thoraxklinik, Heidelberg, Germany
[11] Ben Gurion Univ Negev, Soroka Med Ctr, Beer Sheva, Israel
[12] Westmead Hosp, Sydney, NSW, Australia
[13] Univ Sydney, Sydney, NSW, Australia
[14] German Ctr Lung Res, Airway Res Ctr North, LungenClin, Grosshansdorf, Germany
[15] Kansai Med Univ Hosp, Osaka, Japan
[16] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[17] Chris OBrien Lifehouse, Camperdown, NSW, Australia
[18] Merck & Co Inc, Kenilworth, NJ USA
[19] Univ Las Palmas Gran Canaria, Complejo Hosp Univ Insular Maternoinfantil Gran C, Las Palmas Gran Canaria, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 11期
关键词：
PD-L1; pembrolizumab; chemotherapy; NSCLC;
D O I：
10.1016/j.jtho.2019.09.090
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O.03
引用
收藏
页码：S1153 / S1153
页数：1
相关论文
共 50 条
  • [1] KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.
    Gadgeel, Shirish M.
    Garassino, Marina Chiara
    Esteban, Emilio
    Speranza, Giovanna
    Felip, Enriqueta
    Hochmair, Maximilian J.
    Powell, Steven Francis
    Cheng, Susanna Y.
    Bischoff, Helge
    Peled, Nir
    Hui, Rina
    Reck, Martin
    Kurata, Takayasu
    Garon, Edward B.
    Boyer, Michael J.
    Yang, Jing
    Pietanza, Maria Catherine
    Rodriguez-Abreu, Delvys
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC
    Garassino, M.
    Rodriguez-Abreu, D.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    Speranza, G.
    Reck, M.
    Hui, R.
    Boyer, M.
    Cristescu, R.
    Aurora-Garg, D.
    Albright, A.
    Loboda, A.
    Kobie, J.
    Lunceford, J.
    Ayers, M.
    Lubiniecki, G.
    Piperdi, B.
    Pietanza, M. C.
    Garon, E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S216 - S217
  • [3] Pembrolizumab (pembro) 1 chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407
    Paz-Ares, L.
    Vicente, D.
    Tafreshi, A.
    Robinson, A.
    Soto Parra, H.
    Mazieres, J.
    Hermes, B.
    Cicin, I.
    Medgyasszay, B.
    Beatrix, B.
    Rodriguez Cid, J.
    Okamoto, I.
    Lee, S.
    Ramlau, R.
    Vladimirov, V.
    Cheng, Y.
    Deng, X.
    Bas, T.
    Piperdi, B.
    Halmos, B.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Pembrolizumab plus Pemetrexed-Platinum for Patients with Metastatic Nonsquamous NSCLC and Liver or Brain Metastases: Results from KEYNOTE-189
    Garassino, M. C.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    Speranza, G.
    De Angelis, F.
    Domine, M.
    Clingan, P.
    Hochmair, M. J.
    Powell, S. F.
    Cheng, S. Y. -S.
    Bischoff, H. G.
    Peled, N.
    Grossi, F.
    Jennens, R. R.
    Reck, M.
    Hui, R.
    Garon, E. B.
    Boyer, M.
    Rubio-Viqueira, B.
    Novello, S.
    Kurata, T.
    Gray, J. E.
    Cardellino, A.
    Yang, J.
    Pietanza, M. C.
    Rodriguez-Abreu, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1170 - S1171
  • [5] Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.
    Chiara Garassino, Marina
    Gadgeel, Shirish M.
    Rodriguez-Abreu, Delvys
    Felip, Enriqueta
    Esteban, Emilio
    Speranza, Giovanna
    Hochmair, Maximilian
    Francis Powell, Steven
    Garon, Edward B.
    Hui, Rina
    Nogami, Naoyuki
    Cristescu, Razvan
    Morrissey, Michael
    Loboda, Andrey
    Kobie, Julie
    Ayers, Mark
    Piperdi, Bilal
    Catherine Pietanza, Maria
    Snyder, Alexandra
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo (pbo) plus pem and platinum for metastatic nonsquamous NSCLC
    Garassino, M. C.
    Gadgeel, S. M.
    Speranza, G.
    Felip, E.
    Gonzalez, E. Esteban
    Gomez, M. Domine
    Hochmair, M. J.
    Powell, S. F.
    Bischoff, H.
    Peled, N.
    Grossi, F.
    Jennens, R.
    Reck, M.
    Hui, R.
    Garon, E. B.
    Kurata, T.
    Gray, J. E.
    Schwarzenberger, P. O.
    Jensen, E.
    Abreu, D. Rodriguez
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S992 - S993
  • [7] Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189
    Gadgeel, Shirish
    Gray, Jhanelle E.
    Rizzo, Maria Teresa
    Peterson, Patrick
    Kim, Jong Seok
    Rodriguez-Abreu, Delvys
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (11):
  • [8] Safety of pemetrexed (Pem) plus platinum (Plat) in combination with pembrolizumab (Pembro) for metastatic nonsquamous NSCLC: A post hoc analysis of KEYNOTE-189
    Garon, Edward B.
    Sun, Fangfang
    Muehlenbein, Catherine E.
    Kim, Jong S.
    Gadgeel, Shirish M.
    CANCER RESEARCH, 2020, 80 (16)
  • [9] Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
    Rodriguez-Abreu, D.
    Powell, S. F.
    Hochmair, M. J.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    Speranza, G.
    De Angelis, F.
    Domine, M.
    Cheng, S. Y.
    Bischoff, H. G.
    Peled, N.
    Reck, M.
    Hui, R.
    Garon, E. B.
    Boyer, M.
    Kurata, T.
    Yang, J.
    Pietanza, M. C.
    Souza, F.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2021, 32 (07) : 881 - 895
  • [10] Pembrolizumab plus pemetrexed and platinum vs placebo plus pemetrexed and platinum as first-line therapy for metastatic nonsquamous NSCLC: analysis of KEYNOTE-189 by STK11 and KEAP1 status
    Gadgeel, Shirish M.
    Rodriguez-Abreu, Delvys
    Felip, Enriqueta
    Esteban, Emilio
    Speranza, Giovanna
    Reck, Martin
    Hui, Rina
    Boyer, Michael
    Garon, Edward B.
    Horinouchi, Hidehito
    Cristescu, Razvan
    Aurora-Garg, Deepti
    Loboda, Andrey
    Lunceford, Jared
    Kobie, Julie
    Ayers, Mark
    Piperdi, Bilal
    Pietanza, M. Catherine
    Garassino, Marina C.
    CANCER RESEARCH, 2020, 80 (16)
12345